ANG Lifesciences India Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

ANG Lifesciences India şirketinin toplam hissedar öz sermayesi ₹762.8M ve toplam borcu ₹728.4M olup, bu da borç-öz sermaye oranını 95.5% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹2.4B ve ₹1.7B dir.

Anahtar bilgiler

95.5%

Borç/özkaynak oranı

₹728.37m

Borç

Faiz karşılama oranı	n/a
Nakit	₹57.35m
Eşitlik	₹762.77m
Toplam yükümlülükler	₹1.66b
Toplam varlıklar	₹2.42b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 540694 'nin kısa vadeli varlıkları ( ₹1.8B ) kısa vadeli yükümlülüklerini ( ₹1.4B ) aşıyor.

Uzun Vadeli Yükümlülükler: 540694 şirketinin kısa vadeli varlıkları ( ₹1.8B ) uzun vadeli yükümlülüklerini ( ₹215.9M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 540694 'nin net borç/öz sermaye oranı ( 88% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: 540694 şirketinin borç/öz sermaye oranı son 5 yılda 61.2% seviyesinden 95.5% seviyesine yükseldi.

Borç Kapsamı: 540694 'nin işletme nakit akışı negatif olduğundan borçlar iyi karşılanamıyor.

Faiz Kapsamı: 540694 şirketinin borçlarına ilişkin faiz ödemelerinin EBIT tarafından iyi bir şekilde karşılanıp karşılanmadığını belirlemek için yeterli veri yok.

ANG Lifesciences India Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

ANG Lifesciences India Limited, Annual General Meeting, Sep 30, 2024

First quarter 2025 earnings released: ₹2.35 loss per share (vs ₹1.41 profit in 1Q 2024)

ANG Lifesciences India Limited to Report Q1, 2025 Results on Aug 14, 2024

Full year 2024 earnings released: ₹7.61 loss per share (vs ₹0.20 loss in FY 2023)

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: ₹4.52 loss per share (vs ₹1.36 loss in 3Q 2023)

ANG Lifesciences India Limited to Report Q3, 2024 Results on Feb 14, 2024

New major risk - Market cap size

New major risk - Financial position

Second quarter 2024 earnings released

ANG Lifesciences India Limited Announces Resignation of Neeraj Gupta as Chief Financial Officer

ANG Lifesciences India Limited Appoints Rohit Mittal as Additional Director (Non-Executive Non Independent Director)

ANG Lifesciences India Limited, Annual General Meeting, Sep 30, 2023

First quarter 2024 earnings released: EPS: ₹1.41 (vs ₹3.19 in 1Q 2023)

ANG Lifesciences India Limited to Report Q1, 2024 Results on Aug 14, 2023

New major risk - Market cap size

Full year 2023 earnings released: EPS: ₹0.36 (vs ₹31.11 in FY 2022)

ANG Lifesciences India Limited to Report Q4, 2023 Results on May 30, 2023

Investor sentiment improves as stock rises 15%

Investor sentiment deteriorates as stock falls 20%

Investor sentiment improves as stock rises 18%

Investor sentiment deteriorates as stock falls 25%

Third quarter 2023 earnings released: ₹1.36 loss per share (vs ₹1.03 profit in 3Q 2022)

ANG Lifesciences India Limited to Report Q3, 2023 Results on Feb 14, 2023

ANG Lifesciences India Limited Announces Resignation of Subodh Sharma as Chief Financial Officer

ANG Lifesciences India Limited announced that it expects to receive INR 20 million in funding

Investor sentiment deteriorated over the past week

Second quarter 2023 earnings released

ANG Lifesciences India Limited to Report Q2, 2023 Results on Nov 14, 2022

Investor sentiment improved over the past week

ANG Lifesciences India Limited, Annual General Meeting, Sep 30, 2022

ANG Lifesciences India Limited, Annual General Meeting, Sep 30, 2022

First quarter 2023 earnings released: EPS: ₹3.99 (vs ₹13.03 in 1Q 2022)

ANG Lifesciences India Limited to Report Q1, 2023 Results on Aug 14, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2022 earnings released: EPS: ₹39.09 (vs ₹6.78 in FY 2021)

Investor sentiment improved over the past week

ANG Lifesciences India Limited to Report Q4, 2022 Results on May 30, 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

ANG Lifesciences India Limited Approves Re-Constitution of Committee

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

ANG Lifesciences India Limited (BSE:540694) agreed to acquire ANG Healthcare India Private Limited for INR 40 million.

Investor sentiment deteriorated over the past week

First half 2022 earnings released: EPS ₹32.58 (vs ₹5.31 in 1H 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

ANG Lifesciences India Limited (BSE:540694) acquired Two Formulation Manufacturing Facilities from Ind-Swift Limited (BSE:524652) for INR 600 million.

Company Secretary & Compliance Officer Preeti Goel has left the company

Full year 2021 earnings released: EPS ₹13.56 (vs ₹11.76 in FY 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: ₹84.00

ANG Lifesciences India Limited, Annual General Meeting, Dec 30, 2020

Market bids up stock over the past week

New 90-day high: ₹61.20

ANG Lifesciences India Limited to Report First Half, 2021 Results on Nov 12, 2020

New 90-day high - ₹45.95

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin